Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Italy.
Radiation Oncology, A.O.U. Careggi, University of Florence, Largo Brambilla, 3, 50134 Florence, Italy.
Crit Rev Oncol Hematol. 2021 Mar;159:103242. doi: 10.1016/j.critrevonc.2021.103242. Epub 2021 Feb 2.
To conduct a systematic review and meta-analysis of the role of SBRTdrug combination in patients affected by mRCC and associated oncologic outcomes and toxicity profiles.
We performed a critical review of the Pubmed, Medline, and Embase databases from January 1, 2000 through April 30, 2020 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool.
A total of 6 studies were included, corresponding to a cohort of 216 patients. Tyrosine Kinases Inhibitors were the most widely used drugs in combination with SBRT, being administered in 93% patients. No study reported an increase of radiation-induced toxicity.
SBRT resulted to be safe, without increase in terms of drugs-related adverse events in this setting. Moreover, this approach showed promising clinical outcomes in terms of LC and OS.
对 SBRT 药物联合治疗 mRCC 患者的作用进行系统评价和荟萃分析，评估其与肿瘤学结果和毒性特征的关系。
我们根据 Preferred Reporting Items and Meta-Analyses 声明，对 2000 年 1 月 1 日至 2020 年 4 月 30 日期间的 Pubmed、Medline 和 Embase 数据库进行了严格审查。为了评估所审查文献的总体质量，我们使用了改良 Delphi 工具。
共纳入 6 项研究，共计 216 例患者。酪氨酸激酶抑制剂是与 SBRT 联合应用最广泛的药物，93%的患者接受了该药物治疗。没有研究报告放射性毒性增加。
在这种情况下，SBRT 是安全的，不会增加与药物相关的不良反应。此外，该方法在 LC 和 OS 方面显示出有前途的临床结果。
